Yahoo Αναζήτηση Διαδυκτίου

Αποτελέσματα Αναζήτησης

  1. www.touchprogram.comTOUCH On-Line

    TYSABRI ® (natalizumab) is available only through the TOUCH Prescribing Program TYSABRI Outreach: Unified Commitment to Health. TOUCH On-Line is a web-based tool designed to assist TOUCH Prescribing Program participants in fulfilling their TOUCH Prescribing Program Requirements.

    • Touch On-Line

      TOUCH On-Line is a web-based tool designed to assist TOUCH...

    • How to Enroll

      TOUCH On-Line. How do I enroll in the TOUCH Prescribing...

  2. TOUCH On-Line is a web-based tool designed to: Provide real-time access to data for patients taking TYSABRI. Maintain compliance with the TOUCH Prescribing Program. Reduce administrative burden/paperwork for prescribers and infusion sites. Streamline communication to/from prescribers and infusion sites.

  3. Read about the TOUCH Prescribing Program & what to expect when meeting with a TOUCH-authorized doctor in your area. See full safety & Boxed Warning.

  4. www.touchprogram.com › TTP › tolTOUCHResourcesTOUCH On-Line

    Helpful Information for the Evaluation of New Neurological Symptoms in Patients Receiving TYSABRI. Understanding PML for Gastroenterologists material is a resource for Gastroenterologists, Internists, or other non-Neurology specialists treating TYSABRI patients.

  5. www.touchprogram.com › TTP › tolTOUCHEnrollTOUCH On-Line

    TOUCH On-Line. How do I enroll in the TOUCH Prescribing Program? Prescribers, infusion sites, certified pharmacies associated with infusion sites and patients must all enroll in the TOUCH Prescribing Program in order to prescribe, infuse, dispense or receive TYSABRI. Infusion Sites. Certified Pharmacies.

  6. TOUCH On-Line is a web-based tool designed to: – Provide real-time access to TYSABRI patient data – Maintain compliance with the TOUCH Prescribing Program

  7. TYSABRI® is indicated for inducing and maintaining clinical response and remission in adult patients with moderately to severely active Crohn’s disease with evidence of inflammation who have had an inadequate response to, or are unable to tolerate, conventional CD therapies and inhibitors of TNF-α.

  1. Γίνεται επίσης αναζήτηση για